Form 4: Recursion Pharmaceuticals Director Sells Shares Under 10b5-1 Trading Plan

Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock at an average price of $6.2156 on October 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On October 1, 2024, Blake Borgeson, a director of Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• The shares were sold at prices ranging from $6.09 to $6.56, with a weighted average sale price of $6.2156.
• Following the transaction, Borgeson directly owns 7,098,428 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transaction is a routine sale under a pre-arranged trading plan, and the director still holds a significant number of shares.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Director selling shares could be perceived negatively by investors, although the 10b5-1 plan mitigates this concern.

Industry Context

Sales by insiders are a common occurrence, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. Investors often monitor insider transactions for signals about a company's prospects, but pre-planned sales are generally viewed as less informative.

Comparison to Industry Standards

• Comparing Borgeson's transactions to other directors in similar biotech companies would require analyzing their Form 4 filings.
• The volume of shares sold is relatively small compared to the total shares owned, which is a common pattern for directors diversifying their holdings.
• The use of a 10b5-1 trading plan is a standard practice among corporate insiders to comply with securities regulations, similar to practices at companies like Amgen or Gilead.

Stakeholder Impact

• The sale could have a minor negative impact on shareholder sentiment, but the existence of the 10b5-1 plan should mitigate concerns.

Key Dates